Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT00769795
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 74
- Registration Number
- NCT00757692
- Locations
- 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
- Conditions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT00684905
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00685633
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3588
- Registration Number
- NCT00673205
- Locations
- 🇬🇧
Research Site, Shrewsbury, United Kingdom
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2009-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1218
- Registration Number
- NCT00672282
- Locations
- 🇸🇪
Research Site, Vostervik, Sweden
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00666666
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 95
- Registration Number
- NCT00659438
- Locations
- 🇫🇷
Research Site, Villejuif, France
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT00658697
- Locations
- 🇺🇸
University of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3618
- Registration Number
- NCT00657904
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.